Latest Vaccination Stories

Decision Allows for Broader Access to Vaccine for the Prevention of Pneumococcal Disease in Adults KIRKLAND, QC, Nov. 20, 2012 /CNW/ - Pfizer Canada announced today that the World Health Organization (WHO) has granted an expansion to the prequalification of Pfizer's pneumococcal conjugate vaccine, Prevnar 13, to include immunization of adults 50 years of age and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14,...

BETHESDA, Md., Nov. 15, 2012 /PRNewswire/ -- While pediatric influenza vaccination rates in the United States have increased considerably over the past five years, a new report issued by the National Foundation for Infectious Diseases and its Childhood Influenza Immunization Coalition (CIIC) identified critical gaps that need to be addressed to continue progress. Overall, influenza vaccination rates among children age 6 months to 17 years remained steady at 52 percent, according to...

WASHINGTON, Nov. 15, 2012 /PRNewswire-USNewswire/ -- CoMeD -- As the Inspector General for Health and Human Services names vaccine researcher Poul Thorsen as one of its "Most Wanted" fugitives, the defense of mercury as 'safe in vaccines' seems to be crumbling. In 2010, the Coalition for Mercury-free Drugs (CoMeD, Inc.) submitted an allegation to the Inspector General, that studies showing mercury-containing vaccines to be safe, are fraudulent. Now, a new "wanted" posted featuring...

But researchers, reporting at ASTMH annual meeting, also cite barriers to complete elimination from a surge of cases in Nigeria to intensifying vaccine refusals in Pakistan Polio cases worldwide reached historic lows in 2012, and for the first time there were no new outbreaks beyond countries already harboring the disease, leaving researchers confident that a massive and re-energized international campaign to eradicate polio is on a path to success, according to presentations today at the...

GAITHERSBURG, Md., Nov. 14, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) announced today that data were presented on GenVec's malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 61st Annual Meeting, which took take place in Atlanta, Georgia on November 11-15, 2012. Data presented at the conference highlighted GenVec's success in identifying novel antigens for use in its malarial vaccine development program. Using a proprietary...

BLUE BELL, Pa., Nov. 14, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania (UPenn), adding worldwide rights to technology and intellectual property for novel synthetic vaccines against cancer, infectious diseases and potential biodefense pathogens. These technologies were developed by UPenn Professor David B. Weiner and collaborators. Dr. Weiner is a pioneer in the field of DNA vaccines,...

RED BANK, N.J., and WHITEHOUSE STATION, N.J., Nov. 13, 2012 /PRNewswire/ -- Vaccines play an important part in helping to maintain health and wellness for people of all ages, not just children. Yet 58 percent of American adults admit that they are not aware of the vaccines that are recommended. In fact, the US Centers for Disease Control and Prevention (CDC) has vaccination schedules for preteens, teens and adults, in addition to children. That's why HealthyWomen, a leading...

Sexually-transmitted diseases (STDs) enter the body through the mucosal epithelial cells and the ability to direct pathogen-clearing T-cells to points of infection may be the critical element in developing successful vaccines against these infections. In a study published in the Journal of Clinical Investigation, researchers led by John Schiller at the National Cancer Institute investigated the immune response to intravaginal immunization in mice infected with a form of the HPV virus carrying...

Rapid mutation has long been considered a key to viral adaptation to environmental change. But in the case of the coronavirus responsible for deadly severe acute respiratory syndrome (SARS), collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations cripples the virus's ability to cause disease in animals. In addition, they say this finding may allow scientists to explore a new option for creating safer live...

WORCESTER, Mass. and TORONTO, Nov. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today provided the following update on company initiatives. Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, is in late Phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial...